Results 71 to 80 of about 7,117 (221)

T‐Cell–Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions

European Journal of Haematology, Volume 116, Issue 2, Page 129-141, February 2026.
ABSTRACT Relapsed/refractory (R/R) mantle cell lymphoma (MCL) remains a therapeutic challenge, particularly in patients with high‐risk features or prior exposure to Bruton's tyrosine kinase inhibitors (BTKis). The advent of T‐cell–redirecting immunotherapies, including chimeric antigen receptor T‐cell (CAR‐T) therapy and bispecific antibodies (BsAbs ...
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Massimo Gentile   +10 more
wiley   +1 more source

Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice

Frontiers in Oncology, 2021
Bruton tyrosine kinase (BTK) inhibitors represent an important therapeutic advancement for B cell malignancies. Ibrutinib, the first-in-class BTK inhibitor, is approved by the US FDA to treat patients with chronic lymphocytic leukemia (CLL)/small ...
Susan M. O’Brien, Jennifer R. Brown, John C. Byrd, Richard R. Furman, Paolo Ghia, Jeff P. Sharman, William G. Wierda   +6 more
doaj   +1 more source

Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real‐World Study

Hematological Oncology, Volume 44, Issue 1, January 2026.
ABSTRACT The management of chronic lymphocytic leukemia (CLL) in older patients requires careful balancing of therapeutic efficacy with the risks of treatment intolerance. Frailty assessment is increasingly recognized as a critical determinant of clinical outcomes, but its specific role in guiding therapy with second‐generation Bruton tyrosine kinase ...
Ernesto Vigna, Enrica Antonia Martino, Annalisa Pitino, Raffaella Pasquale, Isacco Ferrarini, Riccardo Moia, Andrea Visentin, Alessandro Sanna, Marina Motta, Massimo Moratti, Paolo Sportoletti, Annalisa Chiarenza, Alessandro Maggi, Valentina Zammit, Michele Merli, Idanna Innocenti, Claudia Giordano, Laura Nocilli, Massimiliano Postorino, Caterina Stelitano, Andrea Ferrario, Anna Maria Frustaci, Marcello Riva, Sara Pepe, Adalberto Ibatici, Stefania Scardino, Paola Anticoli Borza, Laura Ballotta, Salvatrice Mancuso, Francesco Malaspina, Anna Mele, Sara Galimberti, Gioacchino Catania, Annamaria Giordano, Ilaria Angeletti, Luana Schiattone, Elsa Pennese, Rosanna Miccolis, Angelo Fama, Giulio Giordano, Catello Califano, Antonella Bruzzese, Santino Caserta, Giuliana Farina, Pietro Bulian, Giacomo Loseto, Barbara Pocali, Vanessa Innao, Piero Galieni, Vincenzo Fraticelli, Candida Vitale, Azzurra Romeo, Marco Rossi, Ilaria Scortechini, Federico Vozella, Luigi Malandruccolo, Marzia Varettoni, Lucia Morello, Giuseppe Pietrantuono, Esmeralda Conte, Martina Cantelli, Roberta Murru, Daniele Caracciolo, Enrico Derenzini, Valentina Di Martina, Roberto Marasca, Maria Ilaria Del Principe, Amalia Figuera, Francesco Angotzi, Marta Coscia, Nicola Di Renzo, Luca Laurenti, Nicola Amodio, Pellegrino Musto, Francesco Di Raimondo, Arcangelo Liso, Alessandra Tedeschi, Livio Trentin, Gianluca Gaidano, Francesca Romana Mauro, Giovanni Tripepi, Andrea Corsonello, Fortunato Morabito, Valter Gattei, Massimo Gentile   +84 more
wiley   +1 more source

Efficacy and safety of acalabrutinib with best supportive care versus best supportive care in patients with COVID-19 requiring hospitalization. [PDF]

Immunohorizons
The efficacy and safety of acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, was evaluated in 2 phase 2 studies in hospitalized patients with coronavirus disease 2019 (COVID-19) who received acalabrutinib + best supportive care (BSC) versus BSC ...
Scheinberg P, Khoshnevis MR, Robinson PA, Guerreros A, Sato VAH, Fonseca BAL, Prozesky HW, Romero JOC, Fogliatto L, Meisenberg BR, Park DJ, Gupta A, Patel P, Townsley DM, Zheng L, Munugalavadla V.   +15 more
europepmc   +2 more sources

Expanding the Immunologic and Neuronal Landscape of IgE‐Mediated Anaphylaxis

Immunological Reviews, Volume 337, Issue 1, January 2026.
ABSTRACT Anaphylaxis is a life‐threatening immunoglobulin E (IgE)‐mediated type I hypersensitivity reaction with rising prevalence and burden. It involves mast cell degranulation upon cross‐linking of antigen on mast cell‐bound IgE. Mechanisms of IgE‐mediated anaphylaxis remain incompletely understood, particularly the induction of systemic symptoms ...
Ruchi Biswas, Jamie Moore Fried, Maria A. Curotto de Lafaille   +2 more
wiley   +1 more source

The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. [PDF]

, 2019
PurposeDiarrhea is recognized as a common adverse event associated with tyrosine kinase inhibitors (TKIs), with those targeting the ErbB family of receptors being associated with the highest rate of diarrhea.MethodsThis paper reviews data on the ...
Bosserman, Linda, Bryce, Richard, Di Palma, Jack A, Moran, Susan, Olek, Elizabeth, Rugo, Hope S, Tripathy, Debu   +6 more
core  

Low dose Btk inhibitors selectively block platelet activation by CLEC-2 [PDF]

, 2020
Inhibitors of the tyrosine kinase Btk have been proposed as novel antiplatelet agents. In this study we show that low concentrations of the Btk inhibitor ibrutinib block CLEC-2-mediated activation and tyrosine phosphorylation including Syk and PLCγ2 in ...
Brill, Alexander, Campos, Joana, Clifford, Hayley, Eble, Johannes A, Garcia-Quintanilla, Lourdes, Hinds, Joshua, Hughes, Craig E, Huissoon, Aarnoud P, Kavanagh, Deidre M, Khan, Abdullah O, Nicolson, Phillip LR, Nock, Sophie H, Pike, Jeremy A, Pollitt, Alice Y, Poulter, Natalie S, Pratt, Guy, Smith, Christopher W, Watson, Callum N, Watson, Stephanie, Watson, Steve P   +19 more
core   +5 more sources

Assessment of ethnic differences in pharmacokinetics and clinical responses of acalabrutinib between Chinese and White patients with B‐cell malignancies

British Journal of Clinical Pharmacology
The aim of this study was to assess differences between Chinese and White patients in pharmacokinetics (PK) of, and clinical response to, acalabrutinib and its pharmacologically active major metabolite, ACP‐5862, to support recommended dosing in Chinese ...
Tingting Yao, Junjie Ding, Shringi Sharma, Yunfei Li, Qianwei Xu, Peiming Ma   +5 more
semanticscholar   +1 more source

T‐cell immunomodulation occurs with different time kinetics during acalabrutinib and zanubrutinib therapy in chronic lymphocytic leukaemia

British Journal of Haematology, EarlyView.
Maria L. Andersson, Olina Lind, Kia Heimersson, Anna Berglöf, Teresa del Peso Santos, Lucía Peña‐Pérez, Qing Wang, Tom A. Mulder, Rula Zain, Robert Månsson, Richard Rosenquist, C. I. Edvard Smith, Anders Österborg, Marzia Palma   +13 more
wiley   +1 more source

Successful Zanubrutinib Monotherapy in a Rare CNS Presentation of Relapsed CLL

Case Reports in Hematology, Volume 2026, Issue 1, 2026.
Background Central nervous system (CNS) involvement is an infrequent complication of chronic lymphocytic leukemia (CLL), occurring in less than 1% of cases. We report a case of a 63‐year‐old male with a history of CLL previously treated with ibrutinib but discontinued early due to intolerance. As a result, the patient was then treated with obinutuzumab
Vishaal Kunta, Mohammad Ammad-Ud-Din, Melanie Mediavilla-Varela, Javier Pinilla-Ibarz, Yoshito Nishimura   +4 more
wiley   +1 more source